Loading…
Employees: 97
Size NIOX (NIOX.L) is a United Kingdom Health Care company (Medical/Nursing Services) with a market value of $349M, the 344th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £64.00 on 6 Nov 2026.
Performance Over six months the shares gained 1.6%, against -2.5% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 3.3% over the last twelve months (peer median +6.7%); the operating margin is 21.9% (peer median 8.0%).
Valuation It trades at 20.7× forward earnings against a peer median of 15.5× (5th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.8 points above its cost of capital (6.8% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £47.5M | £48.7M | £41.8M | £36.8M | £31.3M |
| Revenue growth | — | +17% | +14% | +18% | — |
| Gross profit | £28.7M | £29.6M | £26.0M | £22.1M | £17.6M |
| EBITDA | £14.7M | £14.8M | £11.9M | £9.00M | £6.40M |
| Net income | £7.00M | £7.00M | £3.70M | £10.7M | £16.1M |
| Free cash flow | £12.5M | £15.6M | £18.0M | £12.1M | £6.70M |
| Capital expenditure | £1.00M | £1.50M | £1.00M | £300,000 | £100,000 |
| Total debt | n/a | £1.00M | £1.50M | £1.10M | £1.00M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NIOX.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -5.7% | 11th highest of 21 |
| 6-month return | +1.6% | -2.5% | 8th highest of 19 |
| Distance from 52-week high | -20.0% | -24.6% | 7th highest of 21 |
| Revenue growth (TTM) | +3.3% | +6.7% | 9th lowest of 21 |
| Operating margin | 21.9% | 8.0% | 3rd highest of 21 |
| Forward P/E | 20.7× | 15.5× | 5th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 3.9% | 8.1% | 8th least demanding of 16 |
| Growth delivered (Del g) | +15.3% | +12.4% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | -11.4 pp | -16.0 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | +8.8 pp | -2.2 pp | 4th highest of 20 |
| EV / EBITDA | 16.5× | 8.4× | 2nd most expensive of 12 |
| Net debt / EBITDA | -1.1× | 1.7× | 4th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NIOX NIOX.L | United Kingdom | $349M | +2% | +3% | 22% | 20.7× | 3.9% | +15.3% |
| Auna AUNA | United States | $346M | -8% | +17% | 13% | 4.7× | -10.5% | +24.4% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -2% | n/a | -15.1% | +9.6% |
| Oncology Institute STLN | United States | $362M | n/a | +38% | -4% | n/a | n/a | n/a |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $324M | -7% | 0% | 31% | 9.6× | -12.3% | +15.4% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 18.5× | -5.5% | +17.9% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | n/a | 22.4% | -5.8% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 25.5× | 12.0% | -1.5% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 17.3× | 3.9% | +2.6% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 13.9× | 8.1% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |